Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 20/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.52 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613384 | 1.00 | MAP3K14 (0.58) | MAP3K14MAP4K4JAK1JAK3TNK2 | |
| SCHEMBL1612870 | 1.00 | MAP3K14 (0.58) | MAP3K14MAP4K4JAK1JAK3TNK2 | |
| SCHEMBL13575138 | 0.91 | MAP3K14 (0.51) | MAP3K14MAP4K4JAK1JAK3TNK2 | |
| SCHEMBL12743915 | 0.86 | MAP3K14 (0.40) | MAP3K14MAP4K4JAK1JAK3TNK2 | |
| SCHEMBL12743933 | 0.86 | MAP3K14 (0.40) | MAP3K14MAP4K4JAK1JAK3TNK2 | |
| SCHEMBL13575137 | 0.84 | MAP3K14 (0.39) | MAP3K14MAP4K4JAK1JAK3TNK2 | |
| SCHEMBL1613804 | 0.84 | MAP3K14 (0.50) | MAP3K14 | |
| SCHEMBL1612514 | 0.82 | MAP3K14 (0.58) | MAP3K14MAP4K4 | |
| SCHEMBL1613896 | 0.81 | MAP3K14 (0.58) | MAP3K14MAP4K4 | |
| SCHEMBL1612839 | 0.81 | MAP3K14 (0.69) | MAP3K14MAP4K4JAK1JAK3TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315751-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | Amgen Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | MAP3K14 17/4885MAP4K4 57/4885JAK1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.